---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-037574"
form_type: "8-K"
ticker: "FULC"
cik: "0001680581"
company_name: "Fulcrum Therapeutics, Inc."
filed_at: "2023-08-03T23:59:59+00:00"
generated_at: "2026-06-12T08:39:49.992057+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Fulcrum Therapeutics reports Q2 net loss $23.8M, closes FSHD trial screening, appoints CFO

## Summary
- Net loss of $23.8M in Q2 2023, improved from $34.1M in Q2 2022; cash $278.2M.
- Screening closed for Phase 3 REACH trial of losmapimod in FSHD; topline data expected Q4 2024.
- Alan A. Musso appointed CFO effective Aug 7, 2023; base salary $450K, 40% target bonus, 432,800 stock option.
- Licensed global rights from CAMP4 for Diamond-Blackfan Anemia; clinical hold for FTX-6058 remains unresolved.
- R&D expenses fell to $17.8M from $25.0M YoY; cash runway into mid-2025.

## SEC filing metadata
- accession: 0000950170-23-037574
- form_type: 8-K
- ticker: FULC
- cik: 0001680581
- company_name: Fulcrum Therapeutics, Inc.
- filed_at: 2023-08-03T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1680581/000095017023037574/0000950170-23-037574-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1680581/000095017023037574/fulc-20230802.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-037574
- JSON: https://secwatch.observer/filing/0000950170-23-037574.json
- Plain text: https://secwatch.observer/filing/0000950170-23-037574.txt

## Key facts
- Earnings Releases
  Fulcrum Therapeutics, Inc. reported financial results for the second quarter of 2023.
  - Period: the second quarter of 2023
  - Result: reported results
  source text: On August 3, 2023, Fulcrum Therapeutics, Inc., or Fulcrum, announced its financial results for the quarter ended June 30, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1680581/000095017023037574/0000950170-23-037574-index.htm
- Executive change
  Alan A. Musso was appointed as Chief Financial Officer and Treasurer at Fulcrum Therapeutics, Inc..
  - Action: appointed
  - Role: Chief Financial Officer and Treasurer
  source text: On August 2, 2023, Fulcrum’s board of directors, or the Board, appointed Alan A. Musso as Fulcrum’s chief financial officer and treasurer, effective August 7, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1680581/000095017023037574/0000950170-23-037574-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.